CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,224 | -82.9% | 49 | -72.5% | 0.00% | – |
| Q4 2021 | $13,000 | -60.6% | 178 | -40.3% | 0.00% | -100.0% |
| Q3 2021 | $33,000 | -46.8% | 298 | -22.8% | 0.00% | -66.7% |
| Q2 2021 | $62,000 | +17.0% | 386 | -10.4% | 0.00% | +50.0% |
| Q1 2021 | $53,000 | -17.2% | 431 | +2.9% | 0.00% | -33.3% |
| Q4 2020 | $64,000 | +255.6% | 419 | +94.9% | 0.00% | +200.0% |
| Q3 2020 | $18,000 | 0.0% | 215 | -10.0% | 0.00% | 0.0% |
| Q2 2020 | $18,000 | +80.0% | 239 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $10,000 | -33.3% | 239 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $15,000 | +66.7% | 239 | +14.4% | 0.00% | 0.0% |
| Q3 2019 | $9,000 | +125.0% | 209 | +178.7% | 0.00% | – |
| Q2 2019 | $4,000 | -99.9% | 75 | 0.0% | 0.00% | – |
| Q1 2019 | $2,679,000 | +25.0% | 75 | 0.0% | 0.00% | – |
| Q4 2018 | $2,143,000 | – | 75 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |